C Diff Treatment

This study is registered with clinicaltrials.gov (Identifier: NCT02667418).

We observed that fidaxomicin and bezlotoxumab are prescribed in similar clinical scenarios, although those treated with bezlotoxumab have greater comorbidity. The proportion of recurrences was numerically lower in those treated with bezlotoxumab, although the propensity analysis did not find signifi …

Nature - Structural analysis of Clostridioides difficile RNA polymerase in complex with fidaxomicin combined with biochemical, genetic and bioinformatic analyses identifies a key residue that...

Fidaxomicin (Fdx) is widely used to treat Clostridioides difficile (Cdiff) infections, but the molecular basis of its narrow-spectrum activity in the human gut microbiome remains unknown. Cdiff infections are a leading cause of nosocomial deaths1. Fidaxomicin, which inhibits RNA polymeras …

Fidaxomicin (Fdx) is widely used to treat Clostridioides difficile (Cdiff) infections, but the molecular basis of its narrow-spectrum activity in the human gut microbiome remains unknown. Cdiff infections are a leading cause of nosocomial deaths1. Fidaxomicin, which inhibits RNA polymeras …

Nature - The RNA polymerase of the bacterial pathogen Clostridioides difficile is selectively targeted by the antibiotic fidaxomicin.

Most antibiotics are double-edged swords. Besides killing the pathogen they are prescribed for, they also decimate beneficial bacteria and change the composition of the gut microbiome. As a result, patients ...

Both fidaxomicin and vancomycin are recommended for treatment of Clostridioides difficile infections, but real-world data suggest fidaxomicin should be the go-to treatment option.

Clostridioides difficile is a commensal Gram-positive gut bacterium that causes C. difficile-associated diarrhea. Currently available antibacterial therapeutic treatment options are effective except for the repeated recurrences significantly burdening the health care system and causing …

Both fidaxomicin and vancomycin are recommended for treatment of Clostridioides difficile infections, but real-world data suggest fidaxomicin should be the go-to treatment option.

Click here to download the C. diff Care Guide

Background and objective Severe Clostridium difficile (C. difficile) infection (CDI)-related colitis is associated with high morbidity and mortality. Current guidelines recommend oral vancomy...

As long as I can recall, I have suffered from stomach pain and intense bloating. In 2018, I began my journey of looking for relief to these symptoms which would lead me down the dark road of contracting recurrent, antibiotic resistant C. diff at the young age of 27. I …

(1) Background: Fidaxomicin has been shown to significantly reduce Clostridioides difficile infection (CDI) recurrences rates in randomized, controlled trials. However, national data from the Veterans Affairs has called the real-world applicability of these findings into question. Therefore, …

Probiotics have been widely used to prevent primary Clostridioides difficile infection (pCDI); however, there are fewer studies on their therapeutic aspects for pCDI. In this study, high doses of Bifidobacterium breve YH68 were used alone or in combination with vancomycin (VAN) and metronidazole (MT …

Improving the prevention and diagnosis of primary Clostridioides difficile infection in older adults could reduce mortality and economic burden, according to recent research.

The investigators assessed and validated 3 rule-based algorithms for C difficile infection detection.

The most common world-wide cause of antibiotic-associated infectious diarrhea and colitis is the toxin producing bacterium, Clostridioides difficile (C. difficile). Here we review the background and characteristics of the bacterium and the toxins produced together with the epidemiology and the compl …

In a series of 7 webinar this programme will develop a full picture of the CDI reaching from the importance of healthy gut microbiota, to its detection and testing methods to current and future therapeutic approaches.

Cases of Clostridioides difficile (C diff) have increasingly been reported outside of typical settings, and a survey of general practitioners in France found that many cases can be managed without hospitalization.

We are delighted to announce the dates for our 2022 National C. diff Advocacy Summit, which will be held on May 1 & 2 Washington, D.C. Registration is free and will open soon. For more information, use the link in our bio! #cdiff #cdifficile #advocacy #advocate #advocacysummit pic.twitter.com/vQ9W7B1FmM— Peggy Lillis Fund (@PeggyFund) March 15, 2022

Over the years, our advocates have made a huge impact on the lives of others. We are looking to grow our advocacy network to drive a patient-led movement. We want YOU to join us! Learn more through the link in our bio#advocate #advocacy #cdiff #awareness #prevention #amr pic.twitter.com/s8junhggRC— Peggy Lillis Fund (@PeggyFund) March 13, 2022

Bezlotoxumab was well tolerated and the incidence of recurrent CDI in a high-risk population for recurrence was only 21.4%.

If CDI laboratory testing is indicated in children with diarrhoea, the likelihood of C. difficile colonisation and co-infection with other intestinal pathogens should be considered. The currently available data support a change in the treatment strategy of CDI in children.

The immunological response against Clostridioides difficile (C. difficile) is crucial for an improved understanding of disease mechanisms and the development of novel therapeutic strategies. From April 2014 to February 2015, adult patients with C. difficile infection (CDI) were recruit …

The Clostridium Difficile Infections market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Clostridium Difficile Infections market. A detailed review of the historical and forecasted Clostridium Difficile Infections market is included in the report, covering drug outreach in the 7MM.   Clostridium Difficile Infections Overview Clostridium difficile […]